The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

George V. Papatheodoridis, Ramazan Idilman, George N. Dalekos, Maria Buti, Heng Chi, Florian van Boemmel, Jose Luis Calleja, Vana Sypsa, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Onur Keskın, Nikolaos Gatselis, Bettina E. Hansen, Maria Lehretz, Juan de la Revilla, Savvoula Savvidou, Anastasia Kourikou, Ioannis VlachogiannakosKostantinos Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Pietro Lampertico

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B'. Together they form a unique fingerprint.

Medicine & Life Sciences